Form 4: MAIA Biotechnology Director Acquires Stock Options

Director Steven M. Chaouki reports acquisition of stock options in MAIA Biotechnology, Inc.

Summary

• Steven M. Chaouki, a director of MAIA Biotechnology, Inc., filed a Form 4 on January 3, 2025, reporting a transaction that occurred on December 31, 2024.
• The transaction involved the acquisition of 10,225 stock options with an exercise price of $1.98.
• These options, granted under the company's 2021 Equity Incentive Plan, vest immediately and are exercisable from the grant date, expiring on December 31, 2034.
• Following the transaction, Chaouki directly owns 10,225 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of options by a director is mildly positive, suggesting confidence, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates